At World ADC 2026, Xcellon Biologics will highlight its innovative, integrated process platform for glycan site-specific conjugation and downstream purification. This approach targets a defined site on the antibody’s glycan structure, enabling a more homogeneous, well-controlled drug-to-antibody ratio (DAR) without antibody engineering, paired with an integrated downstream purification process for a smoother path from development into GMP manufacturing.
Visit us to learn how Xcellon accelerates the path from construct to clinic, and to discuss your program’s conjugation chemistry and manufacturing needs with our scientific team.
